On-Site Meeting on "Building an Innovative Bioindustry Ecosystem" Held in Hwasun, Jeonnam

National Bio Committee, Jeonnam Bio Promotion Agency, and Companies Attend
Significance in Defining Directions for Collaboration Among Hospitals, Companies, and Public Infrastructure

The National Bio Committee held an on-site tour meeting on "Building an Innovative Bioindustry Ecosystem" on the 23rd at the Hwasun National Immunotherapy Innovation Center. Provided by Jeonnam Bio Promotion Agency

The Presidential National Bio Committee held an on-site tour meeting on "Building an Innovative Bioindustry Ecosystem" on September 23 at the Hwasun National Immunotherapy Innovation Center in Jeonnam.

The meeting was attended by the National Bio Committee Support Group, bio companies from the Jeonnam region, Jeonnam Bio Promotion Agency, Chonnam National University Hwasun Hospital, the National Immunotherapy Innovation Center, and other related local organizations. They focused on discussing ways to promote collaboration between the biomedical and vaccine industries and regional hospitals and companies.

The participants agreed that it is urgent to address regulatory and infrastructure limitations faced by local bio companies during commercialization, to establish a systematic full-cycle support system from clinical trials to regulatory approval, to strengthen joint research and clinical linkages between hospitals and companies, and to advance cooperative frameworks for accelerating technology commercialization in the vaccine and immunotherapy sectors.

In particular, Yoon Hoyul, Director of the Jeonnam Bio Promotion Agency, stated, "Government-established public pharmaceutical manufacturing facilities (CDMOs) already exist in Hwasun, Osong, and Daegu. These facilities should be connected with research and development so that new drugs can be produced in small quantities for trial purposes and their quality can be tested in one streamlined process. This would help small and venture companies reduce the initial costs and regulatory burdens that are difficult to bear on their own."

He added, "If the government officially recognizes these public manufacturing facilities as partners in R&D projects and allows the use of facility fees as research expenses, they can be utilized much more easily in the field. When hospitals, companies, and public manufacturing facilities work together as a single team, new drug development will accelerate, essential medicines can be supplied more reliably, and the regional economy will be strengthened."

There was a consensus that this meeting was significant in that it focused on field needs and clarified directions for cooperation among regional hospitals, companies, and public infrastructure. If the discussed tasks lead to institutional improvements, R&D, and connections in workforce and investment, they are expected to enhance the execution capabilities of the Jeonnam bio ecosystem and deliver tangible results that support the commercialization speed of companies.